6 completed, 4 unknown. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Unknown 4 |
| Phase 1 | 4 | Completed 2, Unknown 2 |
Follow Hepatoma: new trials by email Literature Review of Hepatoma trials Research Report on Hepatoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Nivolumab, Relatlimab - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Bristol-Myers Squibb | 266 | 2021-02-04 | 2026-01-08 |
| Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma Regorafenib/Nivolumab - Carcinoma, Hepatocellular, Hepatoma | Phase 2 | Completed | Asan Medical Center | 42 | 2020-06-16 | 2022-12-06 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies CAR-T/TCR-T cells immunotherapy - Esophagus Cancer, Hepatoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 50 | 2019-09-01 | 2021-02-04 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies CAR-T cell immunotherapy - B-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 73 | 2018-03-01 | 2019-12-11 |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma TKM-080301 - Hepatocellular Carcinoma, Hepatoma | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2014-06-01 | 2019-01-16 |
| Sorafenib and TRC105 in Hepatocellular Cancer TRC 105, Sorafenib - Hepatoma, Liver Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-11 | 2019-01-23 |
| Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy Cinobufacin injection - Hepatoma, Cinobufacin Injection | Phase 2 | Unknown | Changhai Hospital | 284 | 2010-11-01 | 2011-06-28 |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma sorafenib, LC Bead-TACE - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Yale University | 50 | 2009-02-01 | 2021-11-11 |
| Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma Bead Block microspheres, Bead + Dox Arm - Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 101 | 2007-11-01 | 2023-08-18 |
| Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Endoscopy ultrasound - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Unknown | Central Texas Veterans Health Care System | 2004-07-01 | 2006-06-07 |
Carcinoma, Hepatocellular (10) · Liver Neoplasms (5) · Esophageal Neoplasms (2) · Glioma (2) · Stomach Neoplasms (2) · Adenoma, Liver Cell (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Leukemia, Myeloid (1) · Liver Neoplasms, Experimental (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1)
Adenocarcinoma (10) · Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Liver Diseases (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Liver Neoplasms (5) · Adenoma (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2)
Nivolumab (2) · Sorafenib (2) · Immunotherapy, Adoptive (1) · TKM-080301 (1) · carotuximab (1) · huachansu (1) · regorafenib (1) · relatlimab (1)
Shenzhen BinDeBio Ltd. (2) · Arbutus Biopharma Corporation (1) · Asan Medical Center (1) · Bristol-Myers Squibb (1) · Central Texas Veterans Health Care System (1) · Changhai Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Yale University (1)
China (5) · United States (5) · South Korea (3) · Singapore (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Hong Kong (1) · Japan (1) · Mexico (1) · New Zealand (1)
Changhoon Yoo, MD, PhD (1) · Karen T Brown, MD (1) · Mark Kowalski, M.D., Ph.D. (1) · Pankaj Singh, MD (1) · Tim F Greten, M.D. (1)
PMID 17543307, PMID 18981929, PMID 26834067, PMID 30598500, PMID 38374347
2018 (1)